Novo Nordisk plans to speculate greater than 16 billion Danish crowns ($2.34 billion) to spice up manufacturing of its weight-loss medication at a website in Chartres, France, scrambling to maintain up with hovering demand.
The Danish drugmaker’s numerous development tasks west of Paris can be accomplished by the tip of 2028 for a big enhance manufacturing of its present and future product portfolio inside critical power illnesses.
“With this, we will – over the coming years – increase our production capacity to be prepared for the increased demand for our medicines and future innovations from our pipeline,” Novo Nordisk stated on Thursday.
It added that the funding provides capability for GLP-1 merchandise, referring to the energetic ingredient in its pioneering weight-loss drug Wegovy and within the lower-dose model Ozempic, which has additionally been used for weight reduction exterior of its accepted use towards diabetes.
The French authorities has pitched the growth plan as an indication of newly restored French industrial competitiveness.
The funding in Chartres, the place Novo already employs practically 2,000 individuals making pre-filled injector pens and insulin, will result in the creation of 500 jobs, the corporate stated.
Novo’s funding mirrors the same transfer by U.S. rival Eli Lilly, which final week laid out plans to construct a $2.5 billion manufacturing website in Germany in response to hovering demand for its new diabetes and weight problems therapies.
